John Dolatowski, MD
Internal Medicine · Hobart, INNPI 1205922218
Payments from drug & device makers
Across 94 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$492
- AstraZeneca$190
- Galderma Laboratories, L.p.$150
- Exact Sciences$123
- Lilly USA, LLC$84
- GSK$80
- plus $656 from 21 others
What the payments were for
- Speaking & faculty fees$1508%
- Food & beverage$1,43181%
- Education$19311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $492 |
| AstraZeneca | 10 | $190 |
| Galderma Laboratories, L.p. | 1 | $150 |
| Exact Sciences | 7 | $123 |
| Lilly USA, LLC | 5 | $84 |
| GSK | 5 | $80 |
| Dexcom, Inc. | 4 | $74 |
| Xeris Pharmaceuticals, Inc. | 4 | $73 |
| Phathom Pharmaceuticals, Inc. | 3 | $62 |
| Bayer | 3 | $50 |
| Abbott | 3 | $47 |
| Teva Pharmaceuticals USA, Inc. | 1 | $47 |
| Pfizer | 2 | $41 |
| AbbVie(2 entities) | 2 | $40 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| BETA Bionics, Inc. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Mylan Specialty L.p. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$1,774 in reported general payments places this provider in the 80th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 193 | $333,256 |
| MounjaroTirzepatide | 111 | $219,609 |
| RybelsusSemaglutide | 64 | $100,801 |
| TrulicityDulaglutide | 50 | $99,836 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $98,440 |
| EliquisApixaban | 63 | $52,023 |
| JanuviaSitagliptin Phosphate | 17 | $25,462 |
| XareltoRivaroxaban | 24 | $20,806 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 35 | $19,819 |
| JardianceEmpagliflozin | 13 | $19,700 |
| EntrestoSacubitril/Valsartan | 16 | $17,710 |
| FarxigaDapagliflozin Propanediol | 18 | $16,420 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $15,497 |
| MyrbetriqMirabegron | 20 | $12,392 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $10,949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $492 | $434,057257 claims |
| Lilly USA, LLCMounjaro, Trulicity | $84 | $319,445161 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $80 | $108,35097 claims |
| PfizerEliquis | $41 | $52,02363 claims |
| Johnson & JohnsonXarelto | $16 | $20,80624 claims |
| Boehringer IngelheimJardiance | $19 | $19,70013 claims |
| AstraZenecaFarxiga | $190 | $16,42018 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $12,39220 claims |
| AbbVieLinzess, Synthroid | $40 | $12,00744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Hobart
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.